Lucio Iannone

Lucio Iannone, PhD, is the Vice President of Venture Investments at Leaps by Bayer, the investment arm of the global life sciences company Bayer, where he manages the health investment team and deal execution. He is involved in the sourcing, screening and mentoring of companies with game-changing science. Dr. Iannone’s expertise is in cell and gene therapy and their application in several therapeutic fields such as oncology, immunology and genetic diseases. As an investor, Dr. Iannone serves on the board of Pyxis Oncology (PYXS,) Immunitas Therapeutics, eGenesis, Mozart Therapeutics, Deka Biosciences and Vesigen. Before joining Leaps by Bayer, he held several senior roles in biotechnology companies and venture capital firms.

Dr. Iannone received his MSc in molecular biology from Cambridge University in Cambridge, England, and his PhD in medicine from Imperial College of London.